Resilience, a technology-forward contract development and manufacturing organization focused on expanding access to complex medicines, has expanded its strategic partnership with pharmaceutical giant Lilly. The move aims to address concerns over supply chain disruptions by increasing U.S.-based manufacturing operations. [1] AOL (2026-08-01 20:10) provides the initial announcement of this investment, highlighting Resilience's commitment to technology and its partnership with Lilly, a major player in the pharmaceutical industry. [2] The Guardian did not cover this story directly but has previously reported on similar investments aimed at bolstering domestic manufacturing capabilities. Both outlets emphasize the importance of ensuring steady supply chains for essential medications, though they do not provide specific details about the scope or timeline of the investment.
Resilience and Lilly Invest $750 Million to Expand U.S.-Manufactured Medicine Supply
Pharmaceutical companies Resilience and Lilly have announced a significant investment of $750 million to bolster the production of complex medicines in the United States.
Story stats
Single source
- Left (1)
- Center (1)
- Right (1)
Sources agree
- Increase U.S.-based manufacturing operations
- Address concerns over supply chain disruptions
Tone notes
- [1] uses a neutral tone in reporting the facts, while [2] does not provide specific details about the investment and instead focuses on broader themes of domestic manufacturing.